Wikisage, the free encyclopedia of the second generation, is digital heritage
Brivaracetam: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
(ref) |
||
Line 2: | Line 2: | ||
4n propyl analog of [[levetiracetam]], this and levetiracetam may have potential in the mangement of progressive myoclonic [[epilepsy|epilepsies]] | 4n propyl analog of [[levetiracetam]], this and levetiracetam may have potential in the mangement of progressive myoclonic [[epilepsy|epilepsies]] | ||
<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670022/pdf/ndt-11-2967.pdf Profile of brivaracetam and its potential in the treatment of epilepsy]</ref> | <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670022/pdf/ndt-11-2967.pdf Profile of brivaracetam and its potential in the treatment of epilepsy]</ref><ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622453/pdf/dddt-9-5719.pdf Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset ]</ref> | ||
==Links== | ==Links== | ||
Revision as of 01:29, 30 March 2016
-
(2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide
4n propyl analog of levetiracetam, this and levetiracetam may have potential in the mangement of progressive myoclonic epilepsies [1][2]
Links
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486827.htm
ATC